BioNTech

May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech BioSpace

Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer new...

BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA statnews.com

BioNTech Stock Is Stuck in the Red. A Cancer Drug Could Change the Narrative. Barron's

BioNTech Unveils Promising Clinical Data for Pumitamig and Gotistobart at ASCO 2026 Quiver Quantitative

ASCO26: After ivonescimab stumble, rivals unveil their own bispecific data FirstWord Pharma